Unmet Needs and Future Perspectives of RET-Positive NSCLC

Author(s):

Heather A. Wakelee, MD, FASCO,Jacob Sands, MD

Panelists discuss the unmet needs and future perspectives in the treatment of RET-positive non–small cell lung cancer (NSCLC), focusing on areas for improvement in therapy and the potential for new treatment strategies.

EP: 1.Patient Case: 67 Year-Old Male With Stage IIIB+ NSCLC Awaiting for Mutation Testing

EP: 2.Next Steps to Stage IIIB NSCLC Patient Case Awaiting Molecular Testing and Usability of Liquid Biopsy

EP: 3.Testing Methodologies and Standards in Metastatic NSCLC

EP: 4.Practical Considerations in Metastatic NSCLC: Access and Timing of Testing

EP: 5.Clinical-Decision Making: When to Treat Advanced NSCLC Without Mutational Results

EP: 6.Initial Approach to Management of RET-Positive NSCLC

EP: 7.Patient and Therapy Considerations Guiding Initiation of Treatment in RET-Positive NSCLC

EP: 8.Considerations for First-Line Targeted Therapies in Metastatic RET-Positive NSCLC

EP: 9.Role of Immunotherapy and Chemotherapy in RET-Positive NSCLC

EP: 10.Managing RET Inhibitor Treatment-Related Adverse Events

EP: 11.Monitoring Patients With RET-Positive NSCLC

Now Viewing

EP: 12.Unmet Needs and Future Perspectives of RET-Positive NSCLC

Dr. Wakelee: Thank you to Dr Sands for this insightful discussion. Before we end, I would like to get some closing thoughts from Dr Sands on unmet needs and future perspectives on the treatment of RET fusion-positive NSCLC.